Goodwin Procter advised Fulcrum Therapeutics on the deal. Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced its underwritten public offering of 9,615,384 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Blueprint Medicines Corporation on the deal while Cooley represented Sixth Street. Blueprint Medicines Corporation (NASDAQ: BPMC) announced its strategic financing collaborations with Sixth...
You must be a Standard 1 Year member to access this content.
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
You must be a Standard 1 Year member to access this content.
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
You must be a Standard 1 Year member to access this content.
